Dainippon Sumitomo Pharma
As of the edition of 20 October 2026, Dainippon Sumitomo Pharma runs 10 drugs, 9 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Stopped | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Amlodipine | none listed | 16 |
| Interferon alfa | none listed | 0 |
| Amphotericin b | none listed | 0 |
| Meropenem | none listed | 0 |
| Irbesartan | none listed | 2 |
| Repaglinide | none listed | 4 |
| Zonisamide | none listed | 10 |
| Blonanserin | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Dainippon Sumitomo Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 1 trials led
- Immune system: 1 trials led
- Skin and connective tissue: 1 trials led